Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Yen‐Shen Lu

机构：National Taiwan University, National Taiwan University Hospital · ORCID：0000-0001-7461-1291

发表论文 467 篇 · 总被引 13478 次 · h-index 48

代表论文

  • Supplementary Figure S4 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
  • Supplementary Table S7 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
  • Table 2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
  • Table 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
  • Supplementary Table S5 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)
  • Supplementary Figure S2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer (2026)